Zoledronic acid prevents decreases in bone mineral density in patients with prostate cancer undergoing combined androgen blockade
Crossref DOI link: https://doi.org/10.1186/2193-1801-3-586
Published Online: 2014-10-08
Published Print: 2014-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Nishizawa, Satoshi
Inagaki, Takeshi
Iba, Akinori
Kikkawa, Kazuro
Kodama, Yoshiki
Matsumura, Nagahide
Kohjimoto, Yasuo
Hara, Isao
Text and Data Mining valid from 2014-10-08
Article History
Received: 17 July 2014
Accepted: 30 September 2014
First Online: 8 October 2014